Coronary Artery Bypass Graft News and Research

RSS

Remaining stocks of Trasylol removed

On Nov. 5, 2007, the U.S. Food and Drug Administration announced that Bayer Pharmaceuticals Corp. agreed to an FDA-requested marketing suspension of Trasylol, a drug used to control bleeding during heart surgery. At that time, preliminary results from a Canadian study suggested an increased risk for death compared to two other drugs used to control bleeding.

15 May 2008

Beta blockers after surgery more risky than beneficial

The results of new research has shown that patients given high doses of beta blocker drugs following non-cardiac surgery were more likely to have a stroke or die. However they were less likely to suffer a heart attack.

13 May 2008

Number of general surgeons in U.S. declined by 26% since 1981

The ratio of practicing general surgeons to patients in the U.S. declined by 26% between 1981 and 2005, according to an analysis published Monday in the Archives of Surgery, Reuters reports.

22 Apr 2008

Rates of death following coronary artery bypass graft surgery decline since 1997

Rates of death following coronary artery bypass graft (CABG) surgery have declined since 1997 while the number of procedures performed has decreased, according to a report in the April issue of Archives of Surgery.

21 Apr 2008

Patients arriving at hospitals in daytime hours get faster, better care compared to off hours

Patients hospitalized with heart attacks tend to get faster and more comprehensive care if they arrive during daytime hours, according to a report in Circulation: Journal of the American Heart Association.

21 Apr 2008

Angina drug ranolazine potentially useful against heart rhythm disorders

A recently approved angina drug may also represent a powerful new treatment for a rare hereditary syndrome that places teens at risk for sudden cardiac death, according to research presented on April 1st at the 57th Annual Scientific Sessions of the American College of Cardiology (ACC) in Chicago.

9 Apr 2008

Minimally invasive, robotically-assisted coronary artery bypass graft surgery

Dr. Robert Poston is a pioneer in the use of robotics for minimally invasive cardiac surgery.

8 Apr 2008

Drug does not appear to reduce risk of heart attack or death following CABG surgery

Use of MC-1 (a naturally occurring metabolite of vitamin B6) before and for 30 days after coronary artery bypass graft surgery did not reduce the risk of heart attack or cardiovascular death, according to a JAMA study being released early online April 1 to coincide with its presentation at the annual conference of the American College of Cardiology.

2 Apr 2008

Warning about deaths and serious reactions linked to blood thinning drug heparin

The Food and Drug Administration (FDA) in the United States says the production of a popular blood thinning drug has been halted temporarily after more than 300 reports of health problems associated with the drug.

13 Feb 2008

Baxter's multiple-dose vial Heparin linked to severe allergic reactions

The U.S. Food and Drug Administration announced today that Baxter Healthcare Corporation has temporarily stopped manufacturing multiple-dose vials of the injectable blood-thinning drug heparin due to reports of serious allergic reactions and hypotension (low blood pressure) in patients who receive high "bolus" doses of the drug.

11 Feb 2008

Daiichi Sankyo, Lilly submit NDA for investigational antiplatelet drug, Prasugrelin U.S.

Daiichi Sankyo Company, Limited and Eli Lilly and Company have announced that on Wednesday, Dec. 26, 2007, they submitted a New Drug Application (NDA) for prasugrel to the U.S. Food and Drug Administration (FDA).

7 Jan 2008

Blood transfusions linked to surgery complications in women

Women die and get infections more often than men after heart surgery because they tend to receive more blood transfusions, which boost the risks of bad outcomes, according to a study published in the December Journal of Women's Health.

13 Dec 2007

Study looks at blood transfusion outcomes in women

3 Dec 2007

Bypass surgery more likely than angioplasty to relieve coronary artery disease pain

Patients with mid-range coronary artery disease are more likely to get relief from painful angina and less likely to have repeat procedures if they get bypass surgery rather than balloon angioplasty with or without a stent, according to a new report by the Agency for Healthcare Research and Quality, part of the U.S. Department of Health and Human Services.

17 Oct 2007

New guidelines for cardiac testing and treatments

People with heart disease should take special precautions before undergoing any kind of surgery, even noncardiac surgery, to reduce their risk of a cardiac event, according to new joint guidelines from the American College of Cardiology and the American Heart Association.

27 Sep 2007

FDA committees recommend continued U.S. marketing for Trasylol

The Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to the U.S. Food and Drug Administration (FDA) held a meeting to discuss the risk /benefit profile of Trasylol (aprotinin injection), a Bayer drug used in coronary artery bypass graft (CABG) surgery.

13 Sep 2007

PET MPI provides a more accurate "picture" of coronary obstruction

Physicians need to know how badly heart vessels are blocked before they can decide how to treat patients at risk of having a heart attack.

17 Aug 2007

Schering-Plough announces licensing of Acadesine

Schering-Plough Corporation has announced the worldwide licensing of acadesine, an investigational, potentially first-in-class adenosine regulating agent (ARA), from PeriCor Therapeutics, Inc., a privately held, specialty biopharmaceutical company.

20 Jul 2007

Obese heart attack patients more likely to survive after treatment than normal weight patients

Obese and very obese patients have a lower risk of dying after they have been treated for heart attacks than do normal weight patients, according to research published in the European Heart Journal today (Wednesday 20 June).

20 Jun 2007

Researchers develop artificial blood vessels from muscle-derived stem cells and a biodegradable polymer

University of Pittsburgh School of Medicine investigators have engineered artificial blood vessels from muscle-derived stem cells (MDSCs) and a biodegradable polymer that exhibit extensive remodeling and remain free of blockages when grafted into rats.

19 Jun 2007